Thursday, 22 February 2018

Abzena and Sartorius Stedim work conjointly

04 January 2018 | News

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites in San Diego and Bristol

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The life sciences company Abzena has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

Abzena has selected Sartorius Stedim to equip its integrated CDMO facilities in Bristol, PA (development and GMP manufacture of antibody drug conjugates) and San Diego, CA (development and GMP manufacture of monoclonal antibodies and other recombinant proteins). 

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently

Sartorius Stedim will provide both facilities with end-to-end process solutions in single-use (SU) format.

It will equip Abzena’s San Diego process development lab with leading industry technologies such as Ambr250, enabling fast scale up to 500L initially and later to the 2000L scale single-use bioreactor for its centre of excellence in clinical manufacturing. 

 “We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets.” Said by Reinhard Vogt,Executive VP Sartorius.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Will the world's largest public healthcare scheme work?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls